Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical R1 and R2 for prophylaxis of acute radiation dermatitis in head and neck cancer
DRKS00003852Phase 4Completed
- Sponsor
- Water-Jel Europe
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of eruca sativa extract R1 and rituximab + lenalidomide in acute radiodermatitis (ARD) and head and neck cancer (HNC) (2 arms), sponsored by Water-Jel Europe. Primary endpoint: Acute radiation dermatitis incidence and severity. Started Mar 2014; status: completed.
02
Drugs
eruca sativa extract R1rituximab + lenalidomide
03
Conditions
acute radiodermatitis (ARD)head and neck cancer (HNC)
Beyond the preview
Go deeper on DRKS00003852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003852.